Pancreatic Ductal Adenocarcinoma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Market Insights | Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report: https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment
• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.
• In May 2024, Hong Kong-based biopharmaceutical company Hutchmed has initiated a Phase II/III clinical trial in China to evaluate surufatinib in combination with other drugs as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The treatment regimen includes surufatinib, camrelizumab from Jiangsu Hengrui Pharmaceuticals, nab-paclitaxel, and gemcitabine.
• In January 2024, Jacobio Pharmaceuticals' pancreatic cancer candidate, glecirasib, has demonstrated improved safety and efficacy compared to previous studies in a Phase I/II trial involving patients with pancreatic cancer and other solid tumors. The Phase I/II monotherapy global study of glecirasib reported a confirmed objective response rate (cORR) of 48% and a disease control rate (DCR) of 90%. These study results will support the submission of a new drug application (NDA) for pancreatic cancer.

Pancreatic Ductal Adenocarcinoma Overview
Due to delayed diagnosis and a poor prognosis, pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, fatal cancer. More than 90% of cases of pancreatic cancer are caused by this form of tumor, which is the most common type and develops in the exocrine compartment.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:
• DCC-3116: Deciphera Pharmaceuticals
• RMC-6236: Revolution Medicines
• SX-682: Syntrix Biosystems
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• CEND-1: Cend Therapeutics Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• KN046: Jiangsu Alphamab Biopharmaceuticals

Pancreatic Ductal Adenocarcinoma Route of Administration
Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment
• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight's Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies at:
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:
Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are - Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:
The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies-
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers
• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers
• However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pancreatic Ductal Adenocarcinoma Report Introduction
2. Pancreatic Ductal Adenocarcinoma Executive Summary
3. Pancreatic Ductal Adenocarcinoma Overview
4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)
7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)
8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)
9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products
10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment
11. Pancreatic Ductal Adenocarcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pancreatic Ductal Adenocarcinoma Key Companies
14. Pancreatic Ductal Adenocarcinoma Key Products
15. Pancreatic Ductal Adenocarcinoma Unmet Needs
16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers
17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion
18. Pancreatic Ductal Adenocarcinoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Pancreatic Ductal Adenocarcinoma Market https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pancreatic Ductal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Latest Reports:

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.